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INTRODUCTION
Hemorrhagic shock (HS) occurs when there is severe blood loss
associated with trauma resulting in a state of global ischemia.
Trauma is the leading cause of death in under-45 year olds in the
USA (Heron et al., 2009), with severe hemorrhage being a leading
cause of preventable death (Stewart et al., 2003). Hemorrhage is
managed by fluid resuscitation with crystalloid fluids and blood
products, including fresh frozen plasma, packed red blood cells and
whole blood transfusions (Finfer et al., 2010), which restore the
circulating volume and cardiac output. However, the return of
oxygen to ischemic tissues promotes the production of reactive
oxygen species and activation of immune cells. This induces a
systemic inflammatory response syndrome that contributes to
apoptosis and tissue necrosis, leading to further organ injury
(Rushing and Britt, 2008). In patients with trauma, failure of more
than four organs is linked to certain mortality, highlighting the need
for interventions that may reduce or prevent the deterioration in
organ injury and function (Fry et al., 1980).
Erythropoietin (EPO) is a 34-KDa glycoprotein secreted by the
kidneys that controls erythropoiesis by regulating the proliferation
of erythroid progenitor cells  in the bone marrow. It acts via an
anti-apoptotic mechanism to prevent death of erythroid
progenitors, allowing them to differentiate into circulating mature
erythrocytes. More recently, EPO has been shown to possess many
pleiotropic actions that are beneficial in various ischemia-
reperfusion-type injuries, including acute kidney injury (Sharples
et al., 2004), myocardial infarction (Brunner et al., 2009), stroke
(Sirén et al., 2001) and HS (Abdelrahman et al., 2004). In the
majority of studies, EPO is administered either during or prior to
reperfusion; however, there are also several studies that have
investigated the protective effects exerted by EPO pre-treatment
in similar contexts. For example, daily pre-treatment with EPO for
a period of 3 days has been demonstrated to protect against the
injury induced by ischemia-reperfusion in the hind-limb (Heeschen
et al., 2003) and kidney (Patel et al., 2004).
Repetitive dosing with EPO could potentially activate numerous
different targets. In particular, EPO is a known stimulus of
endothelial progenitor cell (EPC) mobilization; EPCs are mobilized
in response to hypoxia in order to promote angiogenesis but are
also able to secrete paracrine proteins, which include anti-
inflammatory cytokines such as IL-10 and growth factors including
vascular endothelial growth factor (VEGF) (Heeschen et al., 2003).
EPCs express numerous cell surface markers, which are used to
characterize and identify these cells; examples include CD34,
CD45, CD133, stem cell antigen-1 (sca-1) and vascular endothelial
growth factor receptor-2 (VEGFR2). VEGFR2 is a type III tyrosine
kinase receptor and its activation results in increased proliferation,
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SUMMARY
Pre-treatment with erythropoietin (EPO) has been demonstrated to exert tissue-protective effects against ‘ischemia-reperfusion’-type injuries. This
protection might be mediated by mobilization of bone marrow endothelial progenitor cells (EPCs), which are thought to secrete paracrine factors.
These effects could be exploited to protect against tissue injury induced in cases where hemorrhage is foreseeable, for example, prior to major
surgery. Here, we investigate the effects of EPO pre-treatment on the organ injury and dysfunction induced by hemorrhagic shock (HS). Recombinant
human EPO (1000 IU/kg/day i.p.) was administered to rats for 3 days. Rats were subjected to HS on day 4 (pre-treatment protocol). Mean arterial
pressure was reduced to 35±5 mmHg for 90 minutes, followed by resuscitation with 20 ml/kg Ringer’s lactate for 10 minutes and 50% of the shed
blood for 50 minutes. Rats were sacrificed 4 hours after the onset of resuscitation. EPC (CD34+/flk-1+ cell) mobilization was measured following the
3-day pre-treatment with EPO and was significantly increased compared with rats pre-treated with phosphate-buffered saline. EPO pre-treatment
significantly attenuated organ injury and dysfunction (renal, hepatic and neuromuscular) caused by HS. In livers from rats subjected to HS, EPO
enhanced the phosphorylation of Akt (activation), glycogen synthase kinase-3β (GSK-3β; inhibition) and endothelial nitric oxide synthase (eNOS;
activation). In the liver, HS also caused an increase in nuclear translocation of p65 (activation of NF-κB), which was attenuated by EPO. This data
suggests that repetitive dosing with EPO prior to injury might protect against the organ injury and dysfunction induced by HS, by a mechanism
that might involve mobilization of CD34+/flk-1+ cells, resulting in the activation of the Akt-eNOS survival pathway and inhibition of activation of
GSK-3β and NF-κB.
Pharmacological preconditioning with erythropoietin
attenuates the organ injury and dysfunction induced in
a rat model of hemorrhagic shock
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migration, survival and permeability of vascular endothelial cells
and EPCs. These actions are beneficial in hypoxia as they promote
improved perfusion of ischemic tissues (reviewed by Holmes et al.,
2007). This suggests that EPO-induced mobilization of EPCs could
result in tissue-protective effects either indirectly through the
secretion of paracrine proteins and/or by direct interaction of EPCs
with host cells.
EPO can activate anti-inflammatory and anti-apoptotic pathways
either by interaction with its classical receptor, the EPO receptor
(EPO-R) (reviewed by Chateauvieux et al., 2011), or with the
proposed molecular target responsible for EPO’s tissue-protective
effects, the β common receptor (βcR) (Brines et al., 2004).
Therefore, EPO could have the potential to be used as a therapy
that is administered prior to the onset of an ischemia-reperfusion-
type injury. However, many ischemic insults occur spontaneously
and cannot be predicted (e.g. trauma due to road traffic accident)
and the preferred treatment timepoint is at the location of the
accident or upon hospital admission, i.e. when reperfusion is
performed. Alternatively, in situations where the ischemic insult is
foreseeable, such as prior to major surgery in which blood loss is
likely, EPO pre-treatment could be a viable therapeutic option. EPO
is already clinically used as a treatment prior to surgery in order
to reduce the risk of post-operative anemia and to reduce the
requirement of peri-operative blood transfusions (Naran et al.,
2012; Yoo et al., 2011). It is possible that, in addition to the
erythropoietic effects that EPO exerts in these situations, EPO could
protect tissues against the ischemic damage associated with blood
loss in surgery.
This study investigates whether daily pre-treatment with EPO
for a period of 3 days attenuates the organ injury and dysfunction
induced by HS. We have used a well-characterized rat model of
HS to investigate the early development of the renal and
glomerular dysfunction, and liver and neuromuscular injury
associated with severe hemorrhage and resuscitation (Nandra et
al., 2012; Patel et al., 2011). Having discovered that EPO pre-
treatment does indeed attenuate the organ injury and dysfunction
induced by HS, we investigated the potential mechanism(s)
behind this protective effect by evaluating the ability of EPO to
mobilize EPCs and its effects on the activation of various cellular
signaling pathways [in particular phosphorylation of Akt on
Ser473, phosphorylation of glycogen synthase kinase-3β (GSK-
3β) on Ser9, phosphorylation of eNOS on Ser1177 and activation
of nuclear factor-κB (NF-κB, measured as nuclear translocation
of the p65 subunit)].
RESULTS
Effect of EPO pre-treatment on the circulatory failure caused by
hemorrhagic shock
Compared with sham-operated rats, rats subjected to hemorrhage
exhibited a significant decline in mean arterial pressure (MAP;
P<0.05, Fig. 1). Consequent resuscitation increased MAP but this
was still significantly lower than in sham-operated rats (P<0.05,
Fig. 1). In rats subjected to HS, pre-treatment with EPO had no
significant effect on the decline in MAP; although there was a slight
increase in MAP during the resuscitation phase compared with
phosphate-buffered saline (PBS) pre-treated rats (P>0.05, Fig. 1).
EPO pre-treatment also had no significant effect on the MAP of
sham-operated rats pre-treated with PBS (P>0.05, Fig. 1).
Effect of EPO pre-treatment on the organ injury and dysfunction
induced by hemorrhagic shock
Compared with sham-operated rats pre-treated with PBS, HS-
rats pre-treated with PBS developed significant increases in
serum creatinine (P<0.05, Fig. 2A), AST (P<0.05, Fig. 2C), ALT
(P<0.05, Fig.  2D) and creatine kinase (P<0.05, Fig.  2E), and a
significant decrease in creatinine clearance (P<0.05, Fig.  2B),
indicating the development of renal dysfunction, liver injury,
neuromuscular injury and glomerular dysfunction, respectively.
Pre-treatment of HS-rats with EPO significantly attenuated the
rises in serum creatinine (P<0.05, Fig. 2A), AST (P<0.05, Fig. 2C),
ALT (P<0.05, Fig. 2D) and creatine kinase (P<0.05, Fig. 2E), and
attenuated the decrease in creatinine clearance (P<0.05, Fig. 2B).
There was no significant difference in levels of serum creatinine
(P>0.05, Fig. 2A), AST (P>0.05, Fig. 2C), ALT (P>0.05, Fig. 2D)
and creatine kinase (P>0.05, Fig.  2E), nor in the creatinine
clearance (P>0.05, Fig. 2B) in sham-operated rats treated with PBS
or EPO.
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TRANSLATIONAL IMPACT
Clinical issue
Trauma causes ~6 million deaths every year worldwide. Blood loss or
hemorrhage, which leads to a state of global ischemia, is responsible for 40%
of trauma-related deaths. Gunshot and stab wounds, injuries sustained in road
traffic accidents and invasive surgery can all result in hemorrhage, which can
be managed with fluid resuscitation and blood transfusions. However, because
the combination of hemorrhage and resuscitation can result in global
ischemia-reperfusion-type injuries and hemorrhagic shock, it is common that
organ damage and dysfunction follow the treatment of hemorrhage. Because
the failure of four organs is associated with certain death, there is an urgent
need for pharmaceutical interventions that limit the damage associated with
resuscitation. The hormone erythropoietin (EPO), which controls the
production of red blood cells by regulating the proliferation of erythroid
progenitor cells in the bone marrow, exerts anti-apoptotic and anti-
inflammatory effects in many models of ischemia-reperfusion-type injury,
including hemorrhagic shock. Interestingly, EPO can exert these effects when
given up to 24 hours before the ischemic insult.
Results
In this study, the authors investigate how EPO pre-treatment exerts this tissue-
priming effect. They show that daily treatment of rats with EPO for 3 days prior
to the induction of hemorrhagic shock significantly attenuates renal
(glomerular) dysfunction and liver and neuromuscular injury compared with
pre-treatment with vehicle. Daily treatment of rats for 3 days with EPO results
in mobilization of endothelial progenitor cells. Finally, they show that there is
significant activation of the Akt-eNOS pro-survival pathway in rats pre-treated
with EPO and then subjected to hemorrhagic shock.
Implications and future directions
These findings indicate that the mobilization of endothelial progenitor cells
might contribute to the tissue-protective effects observed with EPO pre-
treatment, either by secretion of anti-inflammatory cytokines, growth factors
and other paracrine proteins and/or by direct interaction with the Akt-eNOS
pro-survival pathway. Importantly, they suggest that pre-treatment of patients
with EPO prior to foreseeable hemorrhage (for example, before surgery) could
be one way to limit the tissue injury associated with hemorrhage and
resuscitation. Finally, the mechanism of action reported here suggests that
dosing with EPO is a possible alternative to using stem cell-based therapies in
other clinical settings because it mobilizes erythroid progenitor cells that, in
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Effect of EPO pre-treatment on the hematocrit and serum EPO
concentration
Compared with PBS pre-treated rats, rats pre-treated with EPO
had a slightly elevated hematocrit (P>0.05, Table 1) and a
significantly higher serum concentration of recombinant human
EPO (rhEPO) (P<0.0001, Table 1); however, this concentration is
less than 0.1 IU/ml.
Effect of EPO concentration on the percentage of circulating
CD34+/flk-1+ cells
Compared with PBS pre-treated rats, pre-treatment with EPO
significantly increased the percentage of CD34+/flk-1+ cells (cells
positive for CD34 and fetal liver kinase-1, the murine homolog of
VEGFR2) present within the mononuclear cell component of the
blood (P<0.05, Fig. 3B); the data are also shown in the form of a
representative histogram (Fig. 3A).
Effect of EPO pre-treatment on the phosphorylation of Akt, GSK-
3β and eNOS, and the nuclear translocation of p65 in the livers of
rats subjected to hemorrhagic shock
EPO is known to activate several cell signaling pathways as a result
of its interaction with the EPO receptor (EPO-R). In particular,
EPO can act on the Akt survival pathway, which could confer
tissue-protective and anti-inflammatory effects; therefore, we
investigated the effect of EPO pre-treatment on the activation of
Akt and proteins that interact with Akt such as GSK-3β (Cross
et al., 1995) and eNOS (Dimmeler et al., 1999). Compared with
sham-operated rats pre-treated with PBS, HS-rats pre-treated
with PBS developed a reduction in the phosphorylation of Akt
on Ser473, GSK-3β on Ser9 and eNOS on Ser1177 in the liver
(P<0.05, Fig. 4A-C). Pre-treatment with EPO attenuated the
decline in phosphorylation induced by HS, therefore restoring the
activity of these proteins to that of sham-operated rats (P<0.05,
Fig. 4A-C).
A downstream effect of the activation of Akt and inhibition of
GSK-3β is the inhibition of the transcription factor NF-κB. The
p65 subunit of NF-κB is known to influence the gene expression
of many proteins that are involved in apoptosis and inflammation.
Compared with sham-operated rats pre-treated with PBS, HS-rats
pre-treated with PBS developed a significant increase in the nuclear
translocation of the p65 NF-κB subunit in the liver, indicating the
activation of NF-κB (P<0.05, Fig.  4D). Pre-treatment with EPO
significantly attenuated the increase in NF-κB activation induced
by HS (P<0.05, Fig. 4D).
There was no significant effect on the phosphorylation of Akt
on Ser473, GSK-3β on Ser9 and eNOS on Ser1177 or on the nuclear
translocation of the p65 NF-κB subunit in the livers of sham-
operated rats pre-treated with EPO compared with those pre-
treated with PBS (P>0.05, Fig. 4A-D).
DISCUSSION
Over the past 20 years, EPO has been reported to reduce tissue
injury in many animal models of disease associated with ischemia-
reperfusion injury (Brunner et al., 2009; Sharples et al., 2004; Sirén
et al., 2001). Here, we demonstrate the tissue-protective action
of EPO when administered as a daily treatment prior to the
induction of hemorrhage. EPO pre-treatment (1000 IU/kg/day i.p.
for 3 days) significantly attenuated the renal (glomerular)
dysfunction and the liver and neuromuscular injury induced by
hemorrhage and resuscitation in the anesthetized rat. This is the
first time this particular pharmacological ‘pre-conditioning’
approach has been used as a therapeutic strategy in a pre-clinical
model of HS.
We have previously reported that administration of EPO prior
to resuscitation (after severe hemorrhage) reduces organ injury and
dysfunction. Specifically, administration of EPO (300 IU/kg i.v. 5
minutes prior to resuscitation) reduced the renal dysfunction and
liver injury caused by hemorrhage and resuscitation in the rat. The
beneficial effect of EPO was associated with prevention of the HS-
induced increase in caspase activity in the kidney (Abdelrahman
et al., 2004); in particular, caspases 3, 8 and 9, which are known to
play a pivotal role in the process of apoptosis (Du et al., 2000). The
degree of protection exerted by EPO in the previous study is
comparable to the degree of protection reported here, indicating
that EPO is still able to induce a protective effect when administered
over a long period prior to hemorrhage. This suggests that during
the 3-day pre-treatment period EPO is able to increase the
resistance of tissues and organs to withstand a later insult.
How does EPO exert this tissue-protective (priming) effect? It
could be argued that continuous treatment with EPO could result
in an increase in basal blood pressure, which could improve the
perfusion of organs. It is reported that a third of patients receiving
long-term EPO treatment do develop hypertension (Rossi et al.,
2011). However, in this study there was no difference in the
baseline MAP values of PBS and EPO pre-treated rats, suggesting
that EPO pre-treatment did not have a hypertensive effect.
Additionally, EPO might improve the perfusion of tissues by
promoting erythropoiesis and increasing the oxygen-carrying
capability of the blood. Long-term EPO treatment is reported to
increase hematocrit in both experimental animals (Brunner et al.,
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Fig. 1. Effect of EPO pre-treatment on the circulatory failure caused by
hemorrhagic shock. Effect of daily EPO pre-treatment over 3 days on MAP in
rats subjected to sham-operation on the fourth day (Sham + PBS 3-day pre-
treatment, n=4; Sham + EPO 3-day pre-treatment, n=4) or hemorrhagic shock
on the fourth day (HS + PBS 3-day pre-treatment, n=12; HS + EPO 3-day pre-
treatment, n=12). Data represent mean ± s.e.m. for n observations; *P<0.05,
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2009) and in patients (Corwin et al., 2007); however, this is often
associated with an increased incidence of thrombotic events
(Corwin et al., 2007). Here, EPO pre-treatment did cause a slight
increase in the hematocrit, although the observed increase was not
statistically significant.
As the half-life of EPO is ~10  hours in the rat when injected
intraperitoneally (Gorio et al., 2005), one could argue that EPO has
accumulated in the plasma so that significant plasma levels of EPO
are still present when the hemorrhage or injury occurs. However,
this was not the case because, even with repetitive injections of
1000 IU/kg of EPO per day, the serum concentration of
recombinant human EPO (i.e. injected EPO) prior to the onset of
hemorrhage was less than 0.1 IU/ml (~6 IU/kg). Although this value
is within the plasma concentration range of EPO that is thought
to afford tissue protection (Brines and Cerami, 2008), we believe
that this serum concentration of EPO would be insufficient to
induce a beneficial effect in our model of HS. In previous studies
investigating the therapeutic effects of EPO in the context of HS,
the lowest dose used was 300 IU/kg (Abdelrahman et al., 2004; Wu
et al., 2010), which would result in a plasma concentration of ~5
IU/ml when injected intravenously. This is 50-fold higher than the
serum concentration measured following 3 days of pre-treatment
with EPO. Taking these studies into account, we would assume that
due to the complex nature of ischaemia-reperfusion injury and
inflammation that occurs in animal models of HS, serum
concentrations lower than 5 IU/ml would be inadequate to exert
a tissue-protective effect.
There is good evidence that EPO acts via the classical EPO-R
present on EPCs to promote their mobilization from the bone
marrow in response to hypoxia in order to induce angiogenesis.
Additionally, EPCs are known to secrete paracrine proteins, which
might contribute to the protective effects we observe in this study
(Heeschen et al., 2003). Repetitive dosing with EPO has been
reported to increase the proportion of circulating EPCs (defined
using combinations of the following markers: CD34, CD45, CD133,
sca-1 and flk-1) in experimental animals (Heeschen et al., 2003)
and in patients (Bahlmann et al., 2004). In this study, EPO pre-
treatment over a period of 3 days significantly increased the
proportion of circulating CD34+/flk-1+ cells. This is approximately
a 100% increase, which is similar to the magnitude of the effect
described by Heeschen and colleagues in mice treated with EPO
(1000 IU/kg/day for 3 days prior to cell analysis); although the
proportion of positive-staining cells appears to be lower in PBS
pre-treated mice than in rats (Heeschen et al., 2003). The
therapeutic potential of EPCs has been assessed in patients with
ST-elevated myocardial infarction; patients received a cell infusion
directly into the left anterior descending coronary artery 5 days
following percutaneous coronary intervention. An average of
dmm.biologists.org704
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Fig. 2. Effect of EPO pre-treatment on the organ
injury and dysfunction induced by hemorrhagic
shock. (A-E)Effect of daily EPO pre-treatment over
3 days on: (A) serum creatinine level as a measure of
renal function; (B) creatinine clearance as a measure
of glomerular function; (C) serum aspartate
aminotransferase and (D) alanine aminotransferase
levels as a measure of liver injury; and (E) serum
creatine kinase level as a measure of
neuromuscular injury. Rats were subjected to sham
operation on the fourth day (Sham + PBS 3-day
pre-treatment, n=4; Sham + EPO 3-day pre-
treatment, n=4) or hemorrhagic shock on the
fourth day (HS + PBS 3-day pre-treatment, n=12; HS
+ EPO 3-day pre-treatment, n=12). Data represent
mean ± s.e.m. for n observations; *P<0.05 versus HS
+ PBS 3-day pre-treatment.
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4.92×109 peripheral blood mononuclear cells were injected, of
which 0.05% were positive for CD34 and VEGFR2. Cellular infusion
resulted in improvement of left ventricular contractile function
during the 6-month follow-up period, presumably as a result of
increased angiogenesis in the infarcted heart (Tatsumi et al., 2007).
Studies using cellular infusions are difficult to conduct because large
numbers of cells are required in order to ensure sufficient delivery
of cells to the diseased tissue. Therefore, the potential of agents
such as EPO (Yip et al., 2011) or granulocyte-macrophage colony-
stimulating factor (Subramaniyam et al., 2009) to promote
mobilization of cells from the bone marrow might be a more
attractive option.
EPO is known to enhance the survival of erythroid progenitor
cells (by reducing their apoptosis) by interacting with the classical
EPO-R to activate several intracellular signaling pathways, in
particular JAK/STAT, PI3K/Akt and MAPK pathways (reviewed
by Chateauvieux et al., 2011). Because the EPO-R is expressed in
many non-hematopoietic tissues including the endothelium
(Anagnostou et al., 1990), brain (Tan et al., 1992), kidneys
(Westenfelder et al., 1999) and heart (Depping et al., 2005), it is
hypothesized that EPO can activate these pathways in other cells
in order to induce a similar anti-apoptotic effect. Therefore, we
investigated the potential effect of EPO pre-treatment on the
activation of these pathways in the livers of rats subjected to HS
and pre-treated with either PBS or EPO. Akt (also known as protein
kinase B), which is a member of the phosphoinositide 3-kinase
signal transduction enzyme family, regulates cellular activation,
inflammatory responses, chemotaxis and apoptosis. When
phosphorylated by its upstream regulator, phosphoinositide-
dependent kinase, Akt modulates cell survival and growth (Cantley,
2002). In this study, HS caused a decline in Akt phosphorylation
and, hence, a decline in activation, which was significantly
attenuated by pre-treatment with EPO. Ruscher and colleagues
demonstrated a similar effect in the brain; where pre-treatment
with EPO up to 48 hours prior to an ischemic insult protected rat
cortical neurons from apoptosis by an Akt-dependent mechanism
(Ruscher et al., 2002).
GSK-3β is a serine-threonine kinase that was originally
recognized as a kinase that phosphorylates glycogen synthase.
Unlike most other kinases, GSK-3β is active in a resting cell state
and is inactivated by phosphorylation of Ser9. GSK-3β is regulated
by multiple signaling pathways including the Akt pathway, which
inactivates it by causing Ser9 phosphorylation (Cross et al., 1995).
Disease Models & Mechanisms 705
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Fig. 3. Effect of EPO concentration on the percentage of circulating
CD34+/flk-1+ cells. (A)Representative histogram from flow cytometry
measurements of circulating CD34+/flk-1+ cells; the red line represents PBS
pre-treated rats and the blue line represents EPO pre-treated rats. (B)Effect of
3-day EPO pre-treatment on the percentage of circulating CD34+/flk-1+ cells in
rats treated for 3 days with either PBS (n=3) or EPO (n=3) and sacrificed
24 hours after the last injection.
Fig. 4. Effect of EPO pre-treatment on the
phosphorylation of Akt, GSK-3β and eNOS,
and the nuclear translocation of p65 in the
livers of rats subjected to hemorrhagic
shock. (A-C)Effect of daily EPO pre-treatment
over 3 days on the phosphorylation of Ser473
on Akt (A), Ser9 on GSK-3β (B) and Ser1177 on
eNOS (C) in the liver. (D)Nuclear translocation
of NF-κB in the livers of rats subjected to sham-
operation on the fourth day (Sham + PBS 3-day
pre-treatment, n=3; Sham + EPO 3-day pre-
treatment, n=3) or hemorrhagic shock on the
fourth day (HS + PBS 3-day pre-treatment, n=3;
HS + EPO 3-day pre-treatment, n=3). Data
represent mean ± s.e.m. for n observations;
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Here, the HS-induced decline in Akt phosphorylation corresponds
to a decline in GSK-3β phosphorylation, which was also significantly
attenuated by EPO pre-treatment. This effect has also been
confirmed in vitro where EPO-induced phosphorylation of Ser9
on GSK-3β was attributable to its anti-apoptotic effect in
cardiomyocytes (Ohori et al., 2008). GSK-3β has many downstream
targets; however, it is able to interact with the transcription factor
NF-κB (Schwabe and Brenner, 2002). NF-κB plays an important
role in regulating the transcription of a number of genes, especially
those involved in producing mediators involved in local and
systemic inflammation, such as cytokines, chemokines, cell
adhesion molecules, apoptotic factors and other mediators
(Senftleben and Karin, 2002). The p65 subunit of NF-κB is thought
to have four phosphorylation sites for the action of GSK-3β, and
specific inhibition of GSK-3β has been shown to directly inhibit
NF-κB-dependent gene transcription (Schwabe and Brenner, 2002).
Also, GSK-3β might inhibit the activation of NF-κB by
phosphorylating and degrading IκBα, which is required to prevent
NF-κB nuclear translocation (Takada et al., 2004). In this study, HS
caused a significant rise in the nuclear translocation of the p65
subunit, which was significantly attenuated by pre-treatment with
EPO. A similar effect was observed when EPO was administered
24 hours prior to induction of myocardial infarction; here EPO pre-
treatment resulted in a significant reduction in infarct size and a
decrease in NF-κB activation in the left ventricle (Xu et al., 2005).
Another downstream effect of Akt activation is the
phosphorylation and activation of eNOS, which results in an
increased production of nitric oxide (NO) in the endothelium. NO
induces local vasodilation, inhibits adhesion of platelets and
neutrophils, and regulates angiogenesis (Luque Contreras et al.,
2006). Here, the phosphorylation of eNOS at the Akt
phosphorylation site; Ser1177, was significantly reduced by HS and
this decline was attenuated by EPO pre-treatment. Su and
colleagues demonstrated that EPO is able to activate eNOS in
endothelial cells by interacting with the βcR and causing Akt-
dependent phosphorylation of eNOS (Su et al., 2011).
The JAK/STAT pathway is also activated by the interaction of
EPO with the EPO-R. This is a type I cytokine receptor but it does
not possess any tyrosine kinase ability, therefore it phosphorylates
JAK proteins, which recruit and activate STAT proteins. They are
then able to dimerize and translocate to the nucleus in order to
influence gene expression (Chateauvieux et al., 2011). STAT3 and
STAT5 are particularly implicated in EPO’s mechanism of action;
however, in this study both HS and EPO pre-treatment had no effect
the phosphorylation of STAT3. EPO is also thought to interact
indirectly with a host of mitogen-activated protein kinases
(MAPKs) through adapter proteins. In particular, activation of
ERK1 and ERK2 promotes cellular stress responses such as
proliferation, differentiation and production of pro-inflammatory
cytokines and occurs in response to injurious stimuli (Donnahoo
et al., 1999; Fukudome et al., 2010). However, in this study there
was no effect on the phosphorylation of ERK1 and ERK2 in PBS
or EPO pre-treated rats subjected to HS.
Pre-treatment of sham-operated rats with EPO did not cause a
significant change in the expression of any of the aforementioned
proteins, which might have been expected over the 3-day treatment
period. However, there was a slight non-significant increase in the
phosphorylation of Akt, GSK-3β and eNOS that might have been
sufficient to have a physiological effect in the liver and so contribute
to the ability of the EPO pre-treated rats to be more resistant to
injury.
The expression of flk-1 on the cell surface of EPCs is of particular
interest because activation of this receptor is known to lead to
interaction with multiple intracellular signaling pathways, which
are similar to those activated by EPO. For example, activation of
flk-1 results in phosphorylation and activation of Akt, which
promotes cell survival by inhibiting the effects of pro-apoptotic
proteins (Gerber et al., 1998a; Gerber et al., 1998b). Additionally,
flk-1-mediated phosphorylation of Akt results in the subsequent
phosphorylation and activation of eNOS (Dimmeler et al., 1999;
Gerber et al., 1998b), which is very similar to the proposed
mechanism of anti-apoptotic action of EPO in endothelial cells (Su
et al., 2011). Flk-1 is also able to interact with ERK1 and ERK2 to
promote cell proliferation (Takahashi et al., 2001). It is possible that
in combination with the ability of EPO to activate pro-survival
signaling pathways, the mobilization of flk-1+ cells is able to
contribute to the tissue-protective effects of EPO by potentiating
the action of these pathways.
The correlation between EPO-induced EPC mobilization and the
beneficial effects of EPO is well documented in the literature.
Several authors have demonstrated the ability of EPO to mobilize
EPCs in animal models (Bahlmann et al., 2003; Heeschen et al.,
2003). This effect has also been observed in stroke patients, where
EPO treatment resulted in an increased proportion of circulating
EPCs, which was associated with a significant and independent
reduction in the incidence of a major adverse neurological event
within 90 days of the initial insult (Yip et al., 2011). Ferrario and
colleagues also demonstrated a similar correlation between
endogenous EPO production and EPC mobilization in patients
following acute myocardial infarction (Ferrario et al., 2007).
Although the direct inhibition of EPO-induced mobilization of
EPCs has not been investigated, it is possible to inhibit EPC
mobilization in animals using pharmacologic agents, for example
with vascular endothelial growth inhibitor (Tian et al., 2009) or
dopamine (Chakroborty et al., 2008). Prevention of the EPC
mobilization afforded by EPO by these interventions could allow
us to differentiate between the EPC-dependent and EPC-
independent effects of EPO. Even if it were possible to block the
mobilization of EPCs afforded by EPO, it is still possible that EPO
causes tissue protection by directly activating pro-survival signaling
pathways.
EPO can activate the above signaling pathways downstream of
its molecular target, which is thought to be a complex consisting
of a single monomer of EPO-R and CD131 (also known as the βcR).
The βcR is a signal-transduction domain that is also present in the
receptor complexes for granulocyte-macrophage colony stimulating
factor, IL-3 and IL-5. The expression of the βcR-EPO-R receptor
complex is known to increase following an injurious stimulus and
it is often described as the tissue-protective receptor. Brines and
colleagues reported that the beneficial effects of EPO are mediated
by this receptor, as demonstrated by the finding that mice lacking
the gene for βcR lost the protection exerted by EPO against spinal
cord injury whereas wild-type mice subjected to the same
procedure did not (Brines et al., 2004). Therefore, it is possible that
the protective effects of EPO pre-treatment observed in this study
are mediated by this receptor complex.
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In conclusion, we report that daily pre-treatment with EPO prior
to hemorrhage attenuates the early organ injury and dysfunction
in rats subjected to severe HS. Pre-treatment with EPO restored
phosphorylation and, hence, activation of Akt, which in turn
resulted in inhibition of GSK-3β (secondary to phosphorylation on
Ser9) and inhibition of the activation of NF-κB. Activation of Akt
also resulted in phosphorylation and activation of eNOS. There is
now very good evidence that therapeutic strategies that enhance
the activation of Akt and reduce the activation of GSK-3β enhance
the resistance of organs to noxious stimuli (including ischemia) and
reduce inflammation via inhibition of NF-κB (Takada et al., 2004).
Due to the lack of effect on the basal blood pressure, hematocrit
and serum EPO concentration, we propose that the mechanism
behind the protective effects exerted by EPO in this study involve
the mobilization of CD34+/flk-1+ cells from the bone marrow,
resulting in activation of the Akt-eNOS survival pathway, which
causes a significant reduction in tissue injury and inflammation by
the inhibition of NF-κB. The pre-treatment regimen used in this
study could provide new therapeutic options for clinical situations
where blood loss is foreseeable; for example, prior to major surgery.
Pre-treatment with EPO also offers an alternative to cell-based
therapies because it can induce the mobilization of EPCs, which
can exert further protection. However, the safety aspects of long-
term treatment with EPO need to be considered carefully as there
is a significant risk associated with increased hematocrit.
MATERIALS AND METHODS
This study was approved by the ethics committee of Queen Mary
University of London and the UK Home Office (PPL: 70/6525) and
all procedures were performed strictly under the United Kingdom
Animals (Scientific Procedures) Act 1986.
Hemorrhagic shock and quantification of organ injury and
dysfunction
This study was carried out on 32 male Wistar rats (Charles River
Ltd, Margate, UK) weighing 283±6 g and receiving a standard diet
and water ad libitum. An additional six rats were used for the
isolation of peripheral blood mononuclear cells. All data from rats
that had died during the experiment were excluded from data
analysis hence the numbers (n) presented represent the ‘survivors’
of the entire experimental protocol.
Rats were anesthetized using sodium thiopentone (120 mg/kg
i.p. maintained using ~10 mg/kg i.v.) and cannulation of the
trachea, femoral artery, carotid artery, jugular vein and bladder was
performed. Blood was withdrawn via a cannula inserted in the right
carotid artery in order to achieve a fall in mean arterial pressure
(MAP) to 35±5 mmHg within 10 minutes. From this point onwards,
MAP was maintained at 35±5 mmHg for a period of 90 minutes,
either by further withdrawal of blood during the compensation
phase or by administration of Ringer’s lactate i.v. during the
decompensation phase. The average volume of blood withdrawn
during hemorrhage was 10.45±0.19 ml (n=24, across all
hemorrhaged groups). At 90 minutes after initiation of hemorrhage,
i.v. resuscitation was performed with 20 ml/kg Ringer’s lactate over
a period of 10 minutes and then half the shed blood mixed with
100 IU/ml heparinized saline over a period of 50 minutes. At the
end of 1 hour of resuscitation, an i.v. infusion of Ringer’s lactate
(1.5 ml/kg/hour) was started as fluid replacement and maintained
throughout the experiment for a further 3 hours, at which point
1.2-ml blood samples were collected via the carotid artery into S/1.3
tubes containing serum gel (Sarstedt, Numbrecht, Germany), after
which the heart was removed to terminate the experiment. The
blood was centrifuged (9000 g for 3  minutes) to separate 
serum. Creatinine, aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and creatine kinase were measured within
24 hours (IDEXX Laboratories, West Yorkshire, UK). Urine was
collected from the cannula inserted into the bladder and creatinine
measured for the estimation of creatinine clearance (IDEXX
Laboratories). Additionally, liver samples were taken and stored at
−80°C.
Experimental design
Rats were randomly allocated into the following groups: (i) sham
+ PBS 3-day pre-treatment (n=4); (ii) sham + EPO 3-day pre-
treatment (n=4); (iii) HS + PBS 3-day pre-treatment (n=12); and
(iv) HS + EPO 3-day pre-treatment (n=12). Rats were treated with
either 1 ml/kg PBS or 1000 IU/kg recombinant human EPO i.p.
daily for 3 days. On day 4, rats were subjected to sham operation
(surgical procedure only) or HS.
Measurement of hematocrit
The hematocrit was measured prior to hemorrhage in rats treated
with either PBS or EPO for 3 days. At 24 hours after the final dose,
~100 μl blood was withdrawn from the cannula inserted in the right
carotid artery and analyzed using an ABL77 v1.41 analyzer
(Radiometer, Brønshøj, Denmark).
Measurement of the serum concentration of recombinant human
EPO concentration
The serum concentration of injected recombinant human EPO
(rhEPO) was measured prior to hemorrhage in rats treated with
either PBS or EPO for 3 days. Approximately 500 μl of blood was
withdrawn 24 hours after the final dose from the cannula inserted
in the right carotid artery. Serum was obtained and analyzed as
per manufacturer’s instructions using a Human EPO Immunoassay
(R&D Systems Europe, Abingdon, UK).
Flow cytometry
The proportion of circulating EPCs was measured in rats treated
with either PBS or EPO for 3 days. Approximately 3 ml blood was
withdrawn 24 hours after the final dose from the cannula inserted
in the right carotid artery. Peripheral blood mononuclear cells
(PBMNCs) were extracted using density gradient centrifugation at
400 g for 30  minutes at 4°C (Histopaque-1077, Sigma-Aldrich,
Dorset, UK). PBMNCs were re-suspended in 10 mls Hank’s
balanced salt solution (HBSS) and centrifuged at 250 g for
10 minutes at 4°C; the resultant supernatant was aspirated and the
pellet re-suspended in 100 μl HBSS. Cells (3×106) were incubated
for 30 minutes at room temperature with 21 μl of mouse anti-CD34
antibody conjugated with fluorescein (FITC) and 24 μl of mouse
anti-flk-1 antibody in 80 μl of HBSS or with HBSS alone. Excess
antibody was removed by washing with 1 ml HBSS, centrifuging
at 330 g for 5 minutes at room temperature and then aspirating
the supernatant. The cells were re-suspended in 5 μl of goat anti-
mouse IgG-phycoerythrin (PE) and incubated for a further
30 minutes at room temperature. The wash step was then repeated
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and cells were re-suspended in 500 μl of HBSS. Analysis was
performed using a Fortessa analyzer (Beckman Coulter, High
Wycombe, UK) and data analyzed using FlowJo v7.6.5 (Ashland,
OR).
Western blot analysis
Western blots were carried out as previously described (Collino et
al., 2006). Three separate experiments of western blot analysis were
performed for each marker, and tissues were done separately for
each western blot experiment. Briefly, rat liver samples were
homogenized and centrifuged at 4000 g for 5  minutes at 4°C.
Supernatants were removed and centrifuged at 15,000 g at 4°C for
40 minutes to obtain the cytosolic fraction. The pelleted nuclei were
resuspended in extraction buffer. The suspensions were centrifuged
at 15,000 g for 20  minutes at 4°C. The resulting supernatants
containing nuclear proteins were carefully removed and the protein
content determined using a bicinchoninic acid (BCA) protein assay
following the manufacturer’s directions. Proteins were separated
by 8% SDS-PAGE and transferred to a polyvinyldenedifluoride
(PVDF) membrane, which was then incubated with a primary
antibody (rabbit anti-total Akt, dilution 1:1000; mouse anti-pAkt
Ser473, dilution 1:1000; rabbit anti-total GSK-3β, dilution 1:200;
goat anti-pGSK-3β Ser9, dilution 1:200; rabbit anti-total eNOS,
dilution 1:200; goat anti-peNOS Ser1177, dilution 1:200; rabbit anti-
NF-κB p65, dilution 1:400). Blots were then incubated with a
secondary antibody conjugated with horseradish peroxidase
(dilution 1:10,000) and developed using the ECL detection system.
The immunoreactive bands were visualized by autoradiography.
The membranes were stripped and incubated with β-actin
monoclonal antibody (dilution 1:5000) and subsequently with an
anti-mouse antibody (dilution 1:10,000) to assess gel-loading
homogeneity. Densitometric analysis of the bands was performed
using Gel ProAnalyzer 4.5, 2000 software (Media Cybernetics,
Silver Spring, MD) and expressed as relative optical density (O.D.).
Optical density analysis was expressed as fold-increase versus the
sham group. In the sham group, the immunoreactive bands of the
gel were measured and normalized against the first immunoreactive
band (standard sham sample) and the results of all the bands
belonging to the same group were expressed as mean ± s.e.m. For
the sham group, a value of 1 is relative to the first immunoreactive
band. The membranes were stripped and incubated with β-actin
monoclonal antibody and subsequently with an anti-mouse
antibody to assess gel-loading homogeneity. Relative band intensity
was assessed and normalized against parallel β-actin expression.
The data for each group was then adjusted against corresponding
sham data to establish relative protein expression compared with
sham animals.
Materials
Unless otherwise stated, all compounds used in this study were
purchased from Sigma-Aldrich (Dorset, UK). All stock solutions
were prepared using non-pyrogenic saline (0.9% w/v NaCl; Baxter
Healthcare, Norfolk, UK). Ringer’s lactate was purchased from
Baxter Healthcare. Antibodies for western blot analyses were
purchased from Santa Cruz Biotechnology (Heidelberg, Germany).
Antibodies for flow cytometry were purchased from Insight
Biotechnology (Middlesex, UK). NeoRecormin (rhEPO) was
manufactured by Roche (Welwyn Garden City, UK).
Statistical analysis
All values described in the text and figures are expressed as mean
± s.e.m. for n observations. Each data point represents
measurements obtained from up to 12 separate animals. Statistical
analysis was carried out using GraphPad Prism 5.03 (GraphPad
Software, San Diego, CA). Data without repeated measurements
were assessed by one-way ANOVA followed by Dunnett’s post hoc
test. Data with repeated measurements were assessed by two-way
ANOVA followed by Bonferroni’s post hoc test. Data with
comparison of only two groups were assessed by unpaired, two-
tailed t-test. A P-value of less than 0.05 was considered to be
significant.
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